David Westenberg
Stock Analyst at Piper Sandler
(4.24)
# 273
Out of 5,182 analysts
186
Total ratings
50.49%
Success rate
16.94%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences | Initiates: Neutral | $21 | $19.17 | +9.55% | 1 | Apr 10, 2026 | |
| GRAL GRAIL | Initiates: Neutral | $54 | $53.76 | +0.45% | 1 | Apr 10, 2026 | |
| WGS GeneDx Holdings | Maintains: Overweight | $160 → $130 | $65.87 | +97.36% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $85.22 | +52.55% | 11 | Feb 24, 2026 | |
| NEO NeoGenomics | Maintains: Overweight | $12 → $13 | $8.73 | +48.91% | 11 | Feb 24, 2026 | |
| LH Labcorp Holdings | Maintains: Neutral | $270 → $300 | $260.99 | +14.95% | 5 | Feb 24, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Neutral | $775 → $750 | $567.48 | +32.16% | 12 | Feb 9, 2026 | |
| ILMN Illumina | Maintains: Overweight | $195 → $170 | $125.61 | +35.34% | 17 | Feb 9, 2026 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $24 → $30 | $22.70 | +32.16% | 11 | Jan 22, 2026 | |
| ZTS Zoetis | Downgrades: Neutral | $190 → $135 | $117.70 | +14.70% | 16 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $6.5 → $10 | $9.40 | +6.44% | 14 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $77.23 | +94.23% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $19 | $21.43 | -11.34% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $80 | $51.28 | +56.01% | 6 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $2 | $1.55 | +29.45% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $230 | $201.50 | +14.14% | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $21 → $30 | $15.28 | +96.36% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7.5 | $4.54 | +65.20% | 10 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $200 | $195.54 | +2.28% | 8 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $13.90 | +43.88% | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $12.11 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $26.94 | - | 1 | Nov 21, 2017 |
Caris Life Sciences
Apr 10, 2026
Initiates: Neutral
Price Target: $21
Current: $19.17
Upside: +9.55%
GRAIL
Apr 10, 2026
Initiates: Neutral
Price Target: $54
Current: $53.76
Upside: +0.45%
GeneDx Holdings
Feb 24, 2026
Maintains: Overweight
Price Target: $160 → $130
Current: $65.87
Upside: +97.36%
Guardant Health
Feb 24, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $85.22
Upside: +52.55%
NeoGenomics
Feb 24, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $8.73
Upside: +48.91%
Labcorp Holdings
Feb 24, 2026
Maintains: Neutral
Price Target: $270 → $300
Current: $260.99
Upside: +14.95%
IDEXX Laboratories
Feb 9, 2026
Maintains: Neutral
Price Target: $775 → $750
Current: $567.48
Upside: +32.16%
Illumina
Feb 9, 2026
Maintains: Overweight
Price Target: $195 → $170
Current: $125.61
Upside: +35.34%
Elanco Animal Health
Jan 22, 2026
Upgrades: Overweight
Price Target: $24 → $30
Current: $22.70
Upside: +32.16%
Zoetis
Jan 22, 2026
Downgrades: Neutral
Price Target: $190 → $135
Current: $117.70
Upside: +14.70%
Jan 12, 2026
Reiterates: Neutral
Price Target: $6.5 → $10
Current: $9.40
Upside: +6.44%
Dec 1, 2025
Initiates: Overweight
Price Target: $150
Current: $77.23
Upside: +94.23%
Nov 11, 2025
Maintains: Neutral
Price Target: $15 → $19
Current: $21.43
Upside: -11.34%
Nov 11, 2025
Maintains: Neutral
Price Target: $105 → $80
Current: $51.28
Upside: +56.01%
Nov 11, 2025
Maintains: Neutral
Price Target: $1.5 → $2
Current: $1.55
Upside: +29.45%
Nov 11, 2025
Maintains: Overweight
Price Target: $220 → $230
Current: $201.50
Upside: +14.14%
Nov 11, 2025
Maintains: Neutral
Price Target: $21 → $30
Current: $15.28
Upside: +96.36%
Nov 11, 2025
Maintains: Overweight
Price Target: $8 → $7.5
Current: $4.54
Upside: +65.20%
Oct 27, 2025
Maintains: Neutral
Price Target: $190 → $200
Current: $195.54
Upside: +2.28%
Oct 15, 2025
Maintains: Overweight
Price Target: $15 → $20
Current: $13.90
Upside: +43.88%
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $12.11
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $26.94
Upside: -